The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADPT | +234.19% | -63.3% | -18.16% | -58% |
| S&P | +17.35% | +108.64% | +15.84% | +133% |
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
One of the company's businesses is particularly hot at the moment.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $58.88M | 36.3% |
| Gross Profit | $37.83M | 79.4% |
| Gross Margin | 64.24% | 15.4% |
| Market Cap | $1.77B | 231.8% |
| Market Cap / Employee | $2.86M | 0.0% |
| Employees | 619 | -12.7% |
| Net Income | -$25.59M | 44.7% |
| EBITDA | -$20.53M | 40.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $43.16M | -27.9% |
| Accounts Receivable | $44.29M | 24.4% |
| Inventory | 8.4 | -36.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $204.91M | -5.3% |
| Short Term Debt | $13.03M | 32.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.42% | 9.2% |
| Return On Invested Capital | -31.33% | -5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.09M | 31.2% |
| Operating Free Cash Flow | -$12.43M | 28.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.13 | 3.95 | 5.42 | 9.29 | 378.96% |
| Price to Sales | 4.26 | 4.95 | 5.85 | 8.63 | 173.04% |
| Price to Tangible Book Value | 6.38 | 8.76 | 13.67 | 25.86 | 633.05% |
| Enterprise Value to EBITDA | -26.44 | -30.22 | -45.65 | -87.25 | 542.12% |
| Return on Equity | -66.7% | -62.4% | -61.0% | -57.5% | -14.05% |
| Total Debt | $224.53M | $222.67M | $220.46M | $217.94M | -3.68% |
ADPT earnings call for the period ending June 30, 2022.
ADPT earnings call for the period ending March 31, 2022.
ADPT earnings call for the period ending December 31, 2021.
ADPT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
